Natural Capsules
NSE: NATCAPSUQ · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Natural Capsules's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Natural Capsules Limited is a manufacturer of hard two-piece gelatin and cellulose capsules for the pharmaceutical and dietary supplement industries. The company has also expanded into the production of steroidal APIs and their derivatives through its subsidiary, Natural Biogenex Private Limited.
Business Model
The company generates revenue through the large-scale manufacturing and sale of pharmaceutical-grade capsules and the development of high-end, patented API technologies. It maintains quality standards through WHO-GMP and ISO certifications to serve both domestic and international pharmaceutical clients.
- Certifications:WHO-GMP, ISO 9001, ISO 140001
Growth Outlook
Growth is driven by the expansion into complex API manufacturing using in-house patented technology. The company continues to cater to the growing demand for non-animal HPMC capsules in the dietary supplement and pharmaceutical sectors.
Key Risks
- Regulatory Compliance. Failure to maintain WHO-GMP and ISO certifications could lead to the suspension of manufacturing operations or loss of key pharmaceutical clients.
- Raw Material Price Volatility. Fluctuations in the cost of gelatin and chemical intermediates can significantly impact profit margins.
- Technological Obsolescence. The company faces the risk that its patented API technologies may be superseded by newer, more cost-effective manufacturing processes.
- Sectoral Competition. The pharmaceutical capsule and API market is highly competitive, potentially leading to pricing pressure and margin erosion.
Start your research today
Unlock AI insights, financials, peers and live data on Natural Capsules and 5,000+ companies — free.
Key Metrics
P/E
-6.8x
Q4 FY26 · consolidated
EV/EBITDA
1632.7x
Q4 FY26 · consolidated
NET PROFIT MARGIN
-8.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.5x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Natural CapsulesNATCAPSUQ | ₹180 Cr | -6.80 | 1632.72 | — | 0.1% | -10.7% | -5.4% | -40.4% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Natural Capsules
NSE: NATCAPSUQ · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Natural Capsules's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Natural Capsules Limited is a manufacturer of hard two-piece gelatin and cellulose capsules for the pharmaceutical and dietary supplement industries. The company has also expanded into the production of steroidal APIs and their derivatives through its subsidiary, Natural Biogenex Private Limited.
Business Model
The company generates revenue through the large-scale manufacturing and sale of pharmaceutical-grade capsules and the development of high-end, patented API technologies. It maintains quality standards through WHO-GMP and ISO certifications to serve both domestic and international pharmaceutical clients.
- Certifications:WHO-GMP, ISO 9001, ISO 140001
Growth Outlook
Growth is driven by the expansion into complex API manufacturing using in-house patented technology. The company continues to cater to the growing demand for non-animal HPMC capsules in the dietary supplement and pharmaceutical sectors.
Key Risks
- Regulatory Compliance. Failure to maintain WHO-GMP and ISO certifications could lead to the suspension of manufacturing operations or loss of key pharmaceutical clients.
- Raw Material Price Volatility. Fluctuations in the cost of gelatin and chemical intermediates can significantly impact profit margins.
- Technological Obsolescence. The company faces the risk that its patented API technologies may be superseded by newer, more cost-effective manufacturing processes.
- Sectoral Competition. The pharmaceutical capsule and API market is highly competitive, potentially leading to pricing pressure and margin erosion.
Start your research today
Unlock AI insights, financials, peers and live data on Natural Capsules and 5,000+ companies — free.
Key Metrics
P/E
-6.8x
Q4 FY26 · consolidated
EV/EBITDA
1632.7x
Q4 FY26 · consolidated
NET PROFIT MARGIN
-8.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.5x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26